title: Activating mutations in HER2: neu opportunities and neu challenges.
abstract: Twenty-five years after the publication of seminal studies showing that HER2 gene amplification and protein overexpression are oncogenic in breast cancer, Bose and colleagues report on the identification of activating HER2 somatic mutations that, albeit rare, may determine the response of breast cancer cells to anti-HER2 agents. These results herald a new era for the potential use of existing HER2-targeted agents for the treatment of patients with HER2-mutant breast cancer.
authors: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
authors: Britta
authors: B
authors: Weigelt
authors: Jorge S
authors: JS
authors: Reis-Filho
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics*; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000235:genetics*; D009154:Mutation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases